Top Cited Articles

The quality and impact of our journals are dependent on many different measures. We’ve provided here some of those metrics for ESMO Open, to reflect the latest 2019 data, that remain important to our authors. We’ve also listed our top most cited articles from each of the last three years.

ESMO Open is indexed in Science Citation Index-Expanded (Web of Science), PubMed Central, Scopus and the DOAJ.


Implementing TMB measurement in clinical practice: considerations on assay requirements
Reinhard Büttner, John W Longshore, Fernando López-Ríos, et al.

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
Giovanni Fucà, Giulia Galli, Marta Poggi, et al.

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology
Rosa Giuliani, Josep Tabernero, Fatima Cardoso, et al.

Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary roundtable discussion
Anna S. Berghoff, Beatriz Bellosillo, Christophe Caux, et al.

How we treat glioblastoma
Michael Weller, Emilie Le Rhun, Matthias Preusser, et al.

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Esmée P. Hoefsmit, Elisa A. Rozeman, John B. A. G. Haanen, Christian U. Blank

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, et al.

New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
Manuel Piechutta, Anna Sophie Berghoffal

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
Chiara Cremolini, Matteo Benelli, Elisa Fontana, et al.

Phase I clinical trial of decitabine (5-aza-2 ‘-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
Yanina J L Jansen, Gontran Verset, Kelly Schats, et al.


Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
Marnix H. Geukes Foppen, Elisa A. Rozeman, Sandra van Wilpe, et al.

Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion
Matthias Preusser, Frank Winkler, Manuel Valiente, et al.

Global cancer control: responding to the growing burden, rising costs and inequalities in access
Gerald W Prager, Sofia Braga, Branislav Bystricky, et al.

Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
Joseph A. Pinto, Carlos S. Vallejos, Luis E. Raez, et al.

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
Charlotte Leduc, Julien Adam, Emilie Louvet, et al.

BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
Jan Norum, Eli Marie Grindedal, Cecilie Heramb, et al.

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
Richard M. Goldberg, Clara Montagut, Zev A. Wainberg, et al.

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
Ji Hyun Park, Jin-Hee Ahn, Sung-Bae Kim

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
Erika Martinelli, Teresa Troiani, Vincenzo Sforza, et al.

Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability
Junhun Cho, Young Hwan Chang, You Jeong Heo, et al.


Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Clemence Granier, Eleonore De Guillebon, Charlotte Blanc, et al.

Cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi, Maria Rosaria Galdiero, Giancarlo Marone, et al.

Multiple primary tumours: challenges and approaches, a review
Alexia Vogt, Sabine Schmid, Karl Heinimann, et al.

Targeting immune checkpoints in breast cancer: an update of early results
Cinzia Solinas, Andrea Gombos, Sofiya Latifyan, et al.

New treatment options for metastatic renal cell carcinoma
Alejo Rodriguez-Vida, Thomas E. Hutson, Joaquim Bellmunt, et al.

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
Fiona Blackhall, D. Ross Camidge, Alice T. Shaw, et al.

Biology of premature ageing in survivors of cancer
Margaret C. Cupit-Link, James L. Kirkland, Kirsten K. Ness, et al.

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
Makoto Nishio, Toyoaki Hida, Shinji Atagi, et al.

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Atsuko Kitano, Makiko Ono, Masayuki Yoshida, et al.

Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
Gary Joseph Doherty, Adam M Duckworth, Susan E Davies, et al.

Journal Metrics:

Days to first decision (mean): 19
Days from acceptance to publication (mean): 38

2 year Impact Factor (JCR): 5.329
SciMago Journal Rank (SJR): 2.018
Eigenfactor: 0.00415
Citescore: 7.0

2019 total content accesses: 288,750
Total Altmetric Mentions: 665